NASDAQ:HBIO - Harvard Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.82 +0.10 (+2.69 %)
(As of 02/18/2019 09:51 AM ET)
Previous Close$3.72
Today's Range$3.72 - $3.90
52-Week Range$2.75 - $6.70
Volume124,651 shs
Average Volume124,481 shs
Market Capitalization$142.46 million
P/E Ratio76.40
Dividend YieldN/A
Beta1.38
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Current SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$101.88 million
Cash Flow$0.1712 per share
Book Value$2.32 per share

Profitability

Net Income$-860,000.00

Miscellaneous

Employees434
Market Cap$142.46 million
OptionableOptionable

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its earnings results on Thursday, October, 25th. The medical instruments supplier reported $0.04 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.04. The medical instruments supplier had revenue of $28.71 million for the quarter, compared to analysts' expectations of $28.50 million. Harvard Bioscience had a negative net margin of 4.18% and a positive return on equity of 5.54%. View Harvard Bioscience's Earnings History.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Harvard Bioscience.

What price target have analysts set for HBIO?

2 equities research analysts have issued 1-year price objectives for Harvard Bioscience's shares. Their predictions range from $11.00 to $11.00. On average, they expect Harvard Bioscience's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 188.0% from the stock's current price. View Analyst Price Targets for Harvard Bioscience.

What is the consensus analysts' recommendation for Harvard Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience.

Has Harvard Bioscience been receiving favorable news coverage?

Press coverage about HBIO stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Harvard Bioscience earned a news impact score of 1.6 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,234,762 shares, an increase of 36.0% from the January 15th total of 907,584 shares. Based on an average daily trading volume, of 179,638 shares, the short-interest ratio is presently 6.9 days. Currently, 3.8% of the company's stock are sold short. View Harvard Bioscience's Current Options Chain.

Who are some of Harvard Bioscience's key competitors?

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the folowing people:
  • Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 53)
  • Ms. Kamalam Unninayar, Chief Financial Officer
  • Mr. Russell J. Sylvia, VP of Global HR
  • Mr. Corey Manchester, VP & Corp. Controller
  • Mr. Karl-Heinz Boven, VP & GM of Electrophysiology

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.22%), Dimensional Fund Advisors LP (5.33%), Royce & Associates LP (4.64%), Acadian Asset Management LLC (2.17%), Essex Investment Management Co. LLC (1.31%) and Algert Global LLC (1.00%). Company insiders that own Harvard Bioscience stock include Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

Which major investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including ARS Investment Partners LLC, Millennium Management LLC, Algert Global LLC, Two Sigma Investments LP, Acadian Asset Management LLC, Essex Investment Management Co. LLC, ClariVest Asset Management LLC and United Services Automobile Association. Company insiders that have sold Harvard Bioscience company stock in the last year include George Uveges, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

Which major investors are buying Harvard Bioscience stock?

HBIO stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP, Alambic Investment Management L.P., BlackRock Inc., Strs Ohio, Squarepoint Ops LLC, Geode Capital Management LLC, Rhumbline Advisers and Mackay Shields LLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $3.82.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $142.46 million and generates $101.88 million in revenue each year. The medical instruments supplier earns $-860,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Harvard Bioscience employs 434 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is http://www.harvardbioscience.com.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]


MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  364
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Consumer Price Index (CPI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel